Madrigal Pharmaceuticals, Inc. officer Shannon Kelley filed a Form 144 notice of proposed sale of 1,077 shares of common stock, dated November 6, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services.

Key Highlights

  • Proposed sale: Shannon Kelley, an officer of Madrigal Pharmaceuticals, intends to sell 1,077 shares of common stock.
  • Aggregate market value: The 1,077 shares carry an aggregate market value of $430,907.70, according to the filing.
  • Source of shares: The securities were acquired through restricted stock units granted by the issuer, acquired on March 5, 2026, with vesting occurring during the period of March 5, 2026 through August 15, 2026.
  • Rule 10b5-1 plan: The filing indicates a plan adoption date of July 31, 2026, in connection with Rule 10b5-1.
  • Prior sales: Kelley sold 664 shares of common stock on August 17, 2026, with gross proceeds of $341,940.08, as reported in the past three months' sales section.
  • Shares outstanding: The filing lists 23,229,561 shares of common stock outstanding as of the notice date.
  • Approximate date of sale: The proposed sale is noted for November 6, 2026, to be executed on NASDAQ.

Kelley's Proposed Stock Sale Under Rule 144 at Madrigal Pharmaceuticals

According to the filing, Shannon Kelley, identified as an officer of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), submitted a Form 144 notice on November 6, 2026, disclosing a proposed sale of 1,077 shares of the company's common stock. The aggregate market value of the shares to be sold is listed as $430,907.70. The broker named for the transaction is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

The filing states that the securities to be sold were acquired through restricted stock units from the issuer, with an acquisition date of March 5, 2026, and a vesting period running from March 5, 2026 through August 15, 2026. The filing's remarks section states: "The securities to be sold were acquired upon the vesting of restricted stock units during the period of 3/5/2026 through 8/15/2026." Kelley indicated reliance on a Rule 10b5-1 plan, with an adoption date of July 31, 2026.

The filing also discloses that, within the prior three months, Kelley sold 664 shares of common stock on August 17, 2026, generating gross proceeds of $341,940.08. The total shares of common stock outstanding are listed as 23,229,561. The issuer's address is 1001 Conshohocken State Road, West Conshohocken, Pennsylvania 19428.

What Was Disclosed

Madrigal Pharmaceuticals officer Shannon Kelley filed a Form 144 on November 6, 2026, proposing to sell 1,077 shares of common stock valued at $430,907.70, acquired through restricted stock units, under a Rule 10b5-1 plan adopted July 31, 2026.